Log in
NASDAQ:ALRN

Aileron Therapeutics Stock Forecast, Price & News

$1.09
+0.02 (+1.87 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.05
Now: $1.09
$1.10
50-Day Range
$1.03
MA: $1.39
$2.29
52-Week Range
$0.25
Now: $1.09
$2.47
Volume425,463 shs
Average Volume575,603 shs
Market Capitalization$44.35 million
P/E RatioN/A
Dividend YieldN/A
Beta3.55
Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company's lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS. It also develops next generation wild type p53 reactivator. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is headquartered in Watertown, Massachusetts.
Read More
Aileron Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALRN
CUSIPN/A
Phone617-995-0900
Employees13

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.31 per share

Profitability

Net Income$-29,370,000.00

Miscellaneous

Market Cap$44.35 million
Next Earnings Date3/29/2021 (Estimated)
OptionableNot Optionable
$1.09
+0.02 (+1.87 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALRN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions

How has Aileron Therapeutics' stock been impacted by Coronavirus?

Aileron Therapeutics' stock was trading at $0.4031 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALRN shares have increased by 170.4% and is now trading at $1.09.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Aileron Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aileron Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Aileron Therapeutics?

Wall Street analysts have given Aileron Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aileron Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aileron Therapeutics' next earnings date?

Aileron Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for Aileron Therapeutics
.

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics, Inc. (NASDAQ:ALRN) announced its quarterly earnings data on Tuesday, November, 17th. The company reported ($0.13) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.13).
View Aileron Therapeutics' earnings history
.

What price target have analysts set for ALRN?

3 brokers have issued 12 month price targets for Aileron Therapeutics' stock. Their forecasts range from $2.00 to $5.00. On average, they anticipate Aileron Therapeutics' stock price to reach $3.50 in the next year. This suggests a possible upside of 221.1% from the stock's current price.
View analysts' price targets for Aileron Therapeutics
.

Are investors shorting Aileron Therapeutics?

Aileron Therapeutics saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 946,200 shares, an increase of 25.1% from the September 30th total of 756,500 shares. Based on an average daily trading volume, of 1,090,000 shares, the days-to-cover ratio is currently 0.9 days. Approximately 4.1% of the company's stock are sold short.
View Aileron Therapeutics' Short Interest
.

Who are some of Aileron Therapeutics' key competitors?

What other stocks do shareholders of Aileron Therapeutics own?

Who are Aileron Therapeutics' key executives?

Aileron Therapeutics' management team includes the following people:
  • Dr. Manuel C. Aivado, Pres, CEO & Director (Age 50, Pay $580.43k)
  • Dr. D. Allen Annis Ph.D., Sr. VP of Research (Age 47, Pay $331.19k)
  • Dr. Vojislav Vukovic M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 53, Pay $411.19k)
  • Mr. Richard J. Wanstall M.B.A., SVP, CFO & Treasurer (Age 51)

When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

Who are Aileron Therapeutics' major shareholders?

Aileron Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (0.10%) and Wedbush Securities Inc. (0.09%). Company insiders that own Aileron Therapeutics stock include Bioventures Ltd Novartis, Jeffrey Allen Bailey, Kathryn Gregory, Reinhard J Ambros, Rickenbach Josef H Von and Vojo Vukovic.
View institutional ownership trends for Aileron Therapeutics
.

Which institutional investors are buying Aileron Therapeutics stock?

ALRN stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, and Wedbush Securities Inc.. Company insiders that have bought Aileron Therapeutics stock in the last two years include Jeffrey Allen Bailey, Kathryn Gregory, Reinhard J Ambros, Rickenbach Josef H Von, and Vojo Vukovic.
View insider buying and selling activity for Aileron Therapeutics
.

How do I buy shares of Aileron Therapeutics?

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aileron Therapeutics' stock price today?

One share of ALRN stock can currently be purchased for approximately $1.09.

How big of a company is Aileron Therapeutics?

Aileron Therapeutics has a market capitalization of $44.35 million. The company earns $-29,370,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Aileron Therapeutics employs 13 workers across the globe.

What is Aileron Therapeutics' official website?

The official website for Aileron Therapeutics is www.aileronrx.com.

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-995-0900 or via email at [email protected]

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.